trial

An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)

NCTId NCT03055338
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 224 (actual)
Sponsored by Merck Sharp & Dohme LLC
Primary completion 2018-01-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
224 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2017-03-08
Primary completion
2018-01-09
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
ElpipodectRisperidone

Sponsors

Merck Sharp & Dohme LLCLead Sponsor

Sites

28 total
Little Rock, United StatesRogers, United StatesBellflower, United StatesCerritos, United StatesGarden Grove, United StatesGlendale, United StatesLemon Grove, United StatesOrange, United StatesPico Rivera, United StatesSan Diego, United StatesSherman Oaks, United StatesTorrance, United States

Linked catalysts

1
An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Sc — primary completion2018-01-09

Facts & assertions

4 sourced
Enrollment
224
Phase
PHASE2
Primary Completion Date
2018-01-09
Status
COMPLETED
relationships
The graph out of here
drug
Elpipodect
drug
Risperidone
drug
lead_sponsor
Merck Sharp & Dohme LLC
company
indication
Schizophrenia, Acute Episode
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Schizophrenia
indication